<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088369</url>
  </required_header>
  <id_info>
    <org_study_id>HM201-AUS-001</org_study_id>
    <nct_id>NCT05088369</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201</brief_title>
  <official_title>A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Himuka AM Pharma Corp.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Syneos Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD &amp; MAD&#xD;
      Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of the study is to assess the safety, tolerability, and PK of single and multiple&#xD;
      intravenous administration of HM201. The study design consists of a SAD study of 4 cohorts, 8&#xD;
      subjects each cohort and a different dose level per cohort. In each cohort 2 will receive the&#xD;
      placebo while rest of group will be administered with HM201. A total of 32 subjects are&#xD;
      planned for the SAD study.&#xD;
&#xD;
      MAD part will begin after cohort 1 and 2 of SAD is completed. MAD will consist of 9 subjects;&#xD;
      2 will receive the placebo while 7 will be administered with HM201. MAD will be conducted in&#xD;
      a dose escalation manner with 4 weekly doses administered to all subjects. One randomization&#xD;
      scheme will be produced for each cohort separately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SAD &amp; MAD study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study will be conducted as a double-blind study. All subjects and clinical personnel will involved in the collection, monitoring, revision, safety and adverse events will be blinded in regards to the subject's treatment assigned of HM201 or the HM201 placebo. All personnel affecting the outcome of the study's treatment assignment will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of treatment-emergent adverse event, serious adverse event and discontinuation.</measure>
    <time_frame>Up to 15 days post last infusion for both SAD &amp; MAD</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of HM201</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 1</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 2</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 3</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Time of peak plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 4</measure>
    <time_frame>MAD: Up to Day 36</time_frame>
    <description>Concentration at the last planned timepoint prior to dosing (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 5</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 6</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Drug clearance (CL) &amp; Clearance at steady state (CLss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 7</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Volume of distribution at steady state (Vss) &amp; during terminal phase (VZ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 8</measure>
    <time_frame>SAD: Up to Day 15. MAD: Up to Day 36</time_frame>
    <description>Half life (T1/2)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>SAD Cohorts 1 to 4: Participants receiving HM201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each SAD cohort participant will be randomized to receive 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg); 0.12 mg/kg (20 nmol/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohorts 1 to 4: Participants Receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each SAD cohort participant will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1 to 4: Participants Receiving HM201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each MAD cohort participant will be randomized to receive a once a week dose of 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg), 0.12 mg/kg (20 nmol/kg) for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1 to 4: Participants Receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each MAD cohort participant will be randomized to receive placebo once a week for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM201</intervention_name>
    <description>HM201 will be administered intravenously.</description>
    <arm_group_label>SAD Cohorts 1 to 4: Participants receiving HM201</arm_group_label>
    <other_name>Pegylated human adrenomedullin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously.</description>
    <arm_group_label>SAD Cohorts 1 to 4: Participants Receiving Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM201</intervention_name>
    <description>HM201 will be administered intravenously.</description>
    <arm_group_label>MAD Cohorts 1 to 4: Participants Receiving HM201</arm_group_label>
    <other_name>Pegylated human adrenomedullin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously.</description>
    <arm_group_label>MAD Cohorts 1 to 4: Participants Receiving Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or non-childbearing potential female&#xD;
&#xD;
          2. BMI ≥18.0 and ≤32.0 kg/m2&#xD;
&#xD;
          3. Good health based on past medical history, medication use, vital signs and physical&#xD;
             exam.&#xD;
&#xD;
          4. Normal renal and hepatic function.&#xD;
&#xD;
          5. Female partners of child bearing potential must agree to use contraception.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant medical history.&#xD;
&#xD;
          2. Significant drug allergy.&#xD;
&#xD;
          3. Use of experimental drug within 3 months prior.&#xD;
&#xD;
          4. Previously received HM201, AM and other derivatives.&#xD;
&#xD;
          5. History of old myocardial infarction.&#xD;
&#xD;
          6. Diagnosed with malignant tumor or history of treatment for malignant tumor.&#xD;
&#xD;
          7. History of drug or alcohol abuse.&#xD;
&#xD;
          8. Use of omitted medicines or substance opposing objective of study.&#xD;
&#xD;
          9. COVID19 vaccine administered within 14 days of initiation of investigational product&#xD;
             or if to receive additional dose within 30 days of investigational product&#xD;
             administration.&#xD;
&#xD;
         10. Use of tobacco/nicotine in excess of ≥ 5 cigarettes a day and unable or unwilling to&#xD;
             prohibit smoking during admission to site.&#xD;
&#xD;
         11. Daily consumption of more than 1L of caffeine/xanthine beverage which cannot be&#xD;
             discontinued more than 24 hours prior to dosing of investigational product and/or ECG&#xD;
             measurement.&#xD;
&#xD;
         12. Regular use of nutraceuticals (e.g., St. John's wort, ginseng, ginkgo biloba, Chinese&#xD;
             herbs, and melatonin) within 1 week before administration of investigational product.&#xD;
&#xD;
         13. Donation of plasma or platelet or 200 mL of whole blood within 4 weeks or 400 mL whole&#xD;
             blood within 3 months before administration of investigational product.&#xD;
&#xD;
         14. Clinically relevant findings in ECG.&#xD;
&#xD;
         15. Systolic blood pressure below 100 mmHg or above 140 mmHg at screening.&#xD;
&#xD;
         16. Diastolic blood pressure above 90 mmHg at screening.&#xD;
&#xD;
         17. Heart rate below 40 beats/min or above 100 beats/min at screening.&#xD;
&#xD;
         18. Symptom of orthostatic hypotension is found at screening or before investigational&#xD;
             product administration (Day -1).&#xD;
&#xD;
         19. Hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb)&#xD;
             hepatitis C virus antibodies (anti-HCV) or human immunodeficiency virus (HIV) antigen&#xD;
             and antibody at screening.&#xD;
&#xD;
         20. Positive to syphilis.&#xD;
&#xD;
         21. Positive to urine drug test.&#xD;
&#xD;
         22. Positive alcohol breath test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristi McLendon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cameron Johnson</last_name>
    <phone>+61 3 9076 8906</phone>
    <email>c.johnson@nucleusnetwork.com.au</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

